A potential energy surface diagram for the attack of cysteine thiolate on compound 506a.
Lead inventor: Michael Pluth
Co-inventors: Matt Cerda, Michael Pluth
Licensing contact: Christine Gramer

1. Technology Overview

The invention focuses on synthesizing thionoesters that release hydrogen sulfide (H2S) upon thiol ligation. These small molecules react with L-cysteine and other cysteine derivatives to release H2S, terminating in the formation of N-benzoyl-L-cysteine. The technology is currently in the development stage, with promising cross-industry applications in biological detection, imaging, and targeted drug delivery.

2. Key Features and Benefits

  • H2S release: Provides optical indication of biological processes.
  • Tunable release kinetics: Enables fine control over release rates.
  • Versatility: Applicable to various industries, including biotechnology and pharmaceuticals.
  • Scalability: Synthesis processes can be scaled for larger quantities.
  • Targeted applications: Ideal for biological detection, imaging, and drug delivery systems.

3. Applications and Market Focus

  • Biological detection: Use in detecting and imaging biological processes involving H2S.
  • Drug delivery: Integration into targeted drug delivery systems.
  • Biotechnology: Development of novel biological detection and imaging methods.
  • Pharmaceutical industry: Synthesis of complex organic molecules for various applications.
  • Chemical industry: Use in advanced synthesis techniques and equipment.

4. Commercial Advantages

  • Strategic benefits: Provides reliable and scalable H2S-releasing compounds for various applications.
  • Implementation advantages: Facilitates integration into existing biological detection and imaging systems.
  • Market positioning: Positions technology as a key enabler for advanced biological detection and drug delivery systems.
  • Competitive advantages: Offers tunable release kinetics and versatility compared to existing methods.

5. Partnership Opportunities

  • Ideal licensing partners: Biotechnology firms, pharmaceutical companies, chemical industry leaders.
  • Cross-sector partnership benefits: Collaboration opportunities across biotechnology and pharmaceutical industries.
  • Diverse market opportunities: Potential for global market expansion in regions with strong biotechnology and pharmaceutical industries.
  • Collaborative development: Opportunities for joint development of hybrid devices and custom synthesis services.
Patent filing: US11078157B1